Satisfaction guaranteed - "Payment by results" for biologic agents

New England Journal of Medicine

Volumn 357, Issue 16, 2007, Pages 1575-1577

  Garber, Alan M ^a,b,c   McClellan, Mark B ^d,e  

^a CENTER FOR HEALTH CARE EVALUATION   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY   (United States)

^d BROOKINGS INSTITUTION   (United States)

^e AMERICAN ENTERPRISE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB;

COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE COST; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MULTIPLE MYELOMA; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 35348976024     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp078204     Document Type: Article

References (4)

1. Institute of Medicine. Rewarding provider performance: aligning incentives in Medicare. Washington, DC: National Academies Press, 2007.
2. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
4. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.